CSPC Pharmaceutical Group Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
CSPC Pharmaceutical Group has a total shareholder equity of CN¥36.5B and total debt of CN¥202.6M, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are CN¥47.9B and CN¥11.4B respectively. CSPC Pharmaceutical Group's EBIT is CN¥7.2B making its interest coverage ratio -32.4. It has cash and short-term investments of CN¥10.8B.
Belangrijke informatie
0.6%
Verhouding schuld/eigen vermogen
CN¥202.56m
Schuld
| Rente dekkingsratio | -32.4x |
| Contant | CN¥10.82b |
| Aandelen | CN¥36.47b |
| Totaal verplichtingen | CN¥11.42b |
| Totaal activa | CN¥47.90b |
Recente financiële gezondheidsupdates
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease
Dec 26Recent updates
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%
Sep 30CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected
Aug 08Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease
Dec 26Analyse van de financiële positie
Kortlopende schulden: 1093's short term assets (CN¥26.5B) exceed its short term liabilities (CN¥10.4B).
Langlopende schulden: 1093's short term assets (CN¥26.5B) exceed its long term liabilities (CN¥988.7M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 1093 has more cash than its total debt.
Schuld verminderen: 1093's debt to equity ratio has increased from 0.5% to 0.6% over the past 5 years.
Schuldendekking: 1093's debt is well covered by operating cash flow (2114.8%).
Rentedekking: 1093 earns more interest than it pays, so coverage of interest payments is not a concern.